Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 3Gastrointestinal Stromal Tumors 2Piebaldism 1Osteosarcoma 1Histiocytoma, Malignant Fibrous 1Diabetes Mellitus, Insulin-Dependent, 12 1Dermatofibrosarcoma 1Chondrosarcoma 1

Interventions

Ifosfamide 5Filgrastim 5Doxorubicin 5Gemcitabine 4Docetaxel 4Radiotherapy 3Proton Therapy 3Carboplatin 3regorafenib 2ivosidenib 2enasidenib 2belinostat 2Sunitinib 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Immune Checkpoint Inhibitors 2HhAntag691 2Fluorouracil 2Etoposide 2Epirubicin 2Cyclophosphamide 2Cisplatin 2Chemotherapy, Adjuvant 2Celecoxib 2Bevacizumab 2venetoclax 1toripalimab 1temsirolimus 1tazemetostat 1tanespimycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chondrosarcoma × envafolimab × Sarcoma × Clear all
NCT05448820 2023-09-21

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Tracon Pharmaceuticals Inc.

Phase 1/2 Unknown
15 enrolled
Sarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Chondrosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡